Physician profile
Bernice Acevedo
NPI 1801117726
$5,944.90
in general payments reported to CMS, 2019-2025
23 companies · $1,253 in 2025
The $1,253 reported for 2025 was more than what 83% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $272 · 2021: $828 · 2022: $685 · 2023: $1,346 · 2024: $1,205 · 2025: $1,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,754 · Education: $49.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,753.60 |
| Education | $49.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,431.40 | 2019-2025 | Farxiga, Lokelma |
| Novo Nordisk INC | $580.27 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $576.51 | 2021-2025 | |
| Vifor Pharma, INC. | $555.67 | 2019-2025 | Veltassa, Korsuva |
| Mallinckrodt Hospital Products INC. | $445.55 | 2020-2025 | Acthar, Terlivaz |
| Aurinia Pharma U.S., INC. | $356.59 | 2021-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $311.62 | 2021-2023 | Benlysta, Jesduvroq |
| Calliditas Therapeutics US INC. | $266.27 | 2023-2025 | Tarpeyo |
| Amgen INC. | $222.43 | 2019-2025 | Tavneos, Repatha, Repatha |
| Fresenius USA Marketing, INC. | $184.52 | 2023-2025 | Velphoro, Velphoro |
| Otsuka America Pharmaceutical, INC. | $174.29 | 2019-2025 | Jynarque |
| Mallinckrodt Enterprises LLC | $164.46 | 2019 | |
| Ardelyx, INC. | $125.71 | 2023-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.18 | 2023-2025 | Jardiance |
| Lilly USA, LLC | $80.75 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $73.28 | 2024 | Vafseo, Auryxia |
| Medtronic, INC. | $59.14 | 2023 | Ellipsys Vascular Access System |
| Alnylam Pharmaceuticals INC. | $56.93 | 2024-2025 | Oxlumo |
| Horizon Therapeutics Plc | $52.22 | 2022-2023 | Krystexxa |
| Travere Therapeutics, INC. | $49.69 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $45.59 | 2024-2025 | |
| Cycle Pharmaceuticals INC | $25.00 | 2024 | Tiopronin |
| Opko Pharmaceuticals, LLC | $22.83 | 2024 | Rayaldee |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernice Acevedo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.